Robert Lufkin, DO
Medical Oncology · Portland, ORNPI 1013932854
Payments from drug & device makers
What this record shows
This record is dominated by education: $41 of the $41 with a category attached, or 100.0%. E.r. Squibb & Sons, L.L.C. accounts for 70.8% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for medical oncology clinicians in OR, where the typical reported total is $810.
Across 3 payments — averaging $13.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$29
- Gilead$12
Across 420 payments — averaging $857.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$208K
- Janssen Research & Development, LLC$121K
- E.r. Squibb & Sons, L.L.C.$31K
- AstraZeneca$479
What the payments were for
- Education$41100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Gilead | 1 | $12 |
How this compares
$41 in reported general payments places this provider in the 15th percentile of 92 medical oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 30 | $709,300 |
| BraftoviEncorafenib | 48 | $699,520 |
| MektoviBinimetinib | 48 | $610,036 |
| JakafiRuxolitinib Phosphate | 33 | $583,644 |
| ImbruvicaIbrutinib | 28 | $543,652 |
| XtandiEnzalutamide | 46 | $490,134 |
| LynparzaOlaparib | 30 | $261,625 |
| Abiraterone Acetate | 231 | $243,396 |
| CalquenceAcalabrutinib Maleate | 21 | $234,448 |
| Lenalidomide | 15 | $207,948 |
| ErleadaApalutamide | 13 | $194,130 |
| EliquisApixaban | 20 | $21,050 |
| XareltoRivaroxaban | 26 | $15,775 |
| Anagrelide Hcl | 12 | $2,322 |
| Tamoxifen Citrate | 35 | $1,578 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Portland
- David PagePortland$238K
- Rachel SanbornPortland$233K
- Matthew TaylorPortland$231K
- Tomasz BeerPortland$102K
- Alison ConlinPortland$85K
- Shivaani KummarPortland$66K
- Stacy LewisPortland$57K
- Hagen KenneckePortland$53K
- Adel KardoshPortland$51K
- Brendan CurtiPortland$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.